Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings

-- Presentations include new preclinical data for PM359, further demonstrating ability of Prime Editors to efficiently, reproducibly and durably correct causative mutation of CGD; on track to enter clinical development in 2024, with initial data expected in 2025 -- -- Prime Medicine Co-Founder, David Liu, Ph.D., Awarded ASGCT Outstanding Achievement Award -- CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class o ...